[1]
González C, García A, Urrea R, del Solar E, Bello H, Zemelman R. [A combination of ampicillin and sulbactam: effect on aerobic and anaerobic gram-negative bacteria]. Revista medica de Chile. 1990 May:118(5):548-54
[PubMed PMID: 2293275]
[2]
Talan DA, Summanen PH, Finegold SM. Ampicillin/sulbactam and cefoxitin in the treatment of cutaneous and other soft-tissue abscesses in patients with or without histories of injection drug abuse. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2000 Aug:31(2):464-71
[PubMed PMID: 10987706]
[3]
Solomkin JS, Mazuski JE, Baron EJ, Sawyer RG, Nathens AB, DiPiro JT, Buchman T, Dellinger EP, Jernigan J, Gorbach S, Chow AW, Bartlett J, Infectious Diseases Society of America. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2003 Oct 15:37(8):997-1005
[PubMed PMID: 14523762]
[4]
McKinnon PS, Neuhauser MM. Efficacy and cost of ampicillin-sulbactam and ticarcillin-clavulanate in the treatment of hospitalized patients with bacterial infections. Pharmacotherapy. 1999 Jun:19(6):724-33
[PubMed PMID: 10391418]
[5]
Geckler RW. A comparison of ampicillin/sulbactam and cefuroxime in the treatment of patients with bacterial infections of the lower respiratory tract. Clinical therapeutics. 1994 Jul-Aug:16(4):662-72
[PubMed PMID: 7982254]
[6]
Jauregui L, Minns P, Hageage G. A comparison of ampicillin/sulbactam versus cefotaxime in the therapy of lower respiratory tract infections in hospitalized patients. Journal of chemotherapy (Florence, Italy). 1995 Apr:7(2):153-6
[PubMed PMID: 7666123]
[7]
Yanagihara K, Fukuda Y, Seki M, Izumikawa K, Higashiyama Y, Miyazaki Y, Hirakata Y, Tomono K, Mizuta Y, Tsukamoto K, Kohno S. Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia. Internal medicine (Tokyo, Japan). 2006:45(17):995-9
[PubMed PMID: 17015999]
Level 2 (mid-level) evidence
[8]
Kadowaki M, Demura Y, Mizuno S, Uesaka D, Ameshima S, Miyamori I, Ishizaki T. Reappraisal of clindamycin IV monotherapy for treatment of mild-to-moderate aspiration pneumonia in elderly patients. Chest. 2005 Apr:127(4):1276-82
[PubMed PMID: 15821205]
[9]
Grayson ML, Gibbons GW, Habershaw GM, Freeman DV, Pomposelli FB, Rosenblum BI, Levin E, Karchmer AW. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 1994 May:18(5):683-93
[PubMed PMID: 8075257]
[10]
Kanra G, Seçmeer G, Gönç EN, Ceyhan M, Ecevit Z. Periorbital cellulitis: a comparison of different treatment regimens. Acta paediatrica Japonica : Overseas edition. 1996 Aug:38(4):339-42
[PubMed PMID: 8840541]
[11]
Jellison TK, Mckinnon PS, Rybak MJ. Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam. Pharmacotherapy. 2001 Feb:21(2):142-8
[PubMed PMID: 11213849]
[12]
Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Tleyjeh IM, Rybak MJ, Barsic B, Lockhart PB, Gewitz MH, Levison ME, Bolger AF, Steckelberg JM, Baltimore RS, Fink AM, O'Gara P, Taubert KA, American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2015 Oct 13:132(15):1435-86. doi: 10.1161/CIR.0000000000000296. Epub 2015 Sep 15
[PubMed PMID: 26373316]
[13]
Straub A, Stapf M, Fischer M, Vollmer A, Linz C, Lâm TT, Kübler A, Brands RC, Scherf-Clavel O, Hartmann S. Bone Concentration of Ampicillin/Sulbactam: A Pilot Study in Patients with Osteonecrosis of the Jaw. International journal of environmental research and public health. 2022 Nov 13:19(22):. doi: 10.3390/ijerph192214917. Epub 2022 Nov 13
[PubMed PMID: 36429636]
Level 3 (low-level) evidence
[14]
Nakayama T, Suzuki M, Yamaguchi Y, Iikura M, Izumi S, Takeda Y, Hojo M, Sugiyama H. Infectious Pulmonary Artery Pseudoaneurysm That Resolved with Conservative Treatment. Internal medicine (Tokyo, Japan). 2022 Oct 15:61(20):3089-3093. doi: 10.2169/internalmedicine.9021-21. Epub 2022 Mar 12
[PubMed PMID: 35283388]
[15]
Ghooi RB, Thatte SM. Inhibition of cell wall synthesis--is this the mechanism of action of penicillins? Medical hypotheses. 1995 Feb:44(2):127-31
[PubMed PMID: 7596307]
[16]
Crass RL, Pai MP. Pharmacokinetics and Pharmacodynamics of β-Lactamase Inhibitors. Pharmacotherapy. 2019 Feb:39(2):182-195. doi: 10.1002/phar.2210. Epub 2019 Jan 20
[PubMed PMID: 30589457]
[17]
Penwell WF, Shapiro AB, Giacobbe RA, Gu RF, Gao N, Thresher J, McLaughlin RE, Huband MD, DeJonge BL, Ehmann DE, Miller AA. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrobial agents and chemotherapy. 2015 Mar:59(3):1680-9. doi: 10.1128/AAC.04808-14. Epub 2015 Jan 5
[PubMed PMID: 25561334]
[18]
Sittner A, Ben-Shmuel A, Glinert I, Bar-David E, Schlomovitz J, Kobiler D, Weiss S, Levy H. Using old antibiotics to treat ancient bacterium-β-lactams for Bacillus anthracis meningitis. PloS one. 2020:15(2):e0228917. doi: 10.1371/journal.pone.0228917. Epub 2020 Feb 13
[PubMed PMID: 32053632]
[19]
Li L, Guo C, Ai L, Dou C, Wang G, Sun H. Research on degradation of penicillins in milk by β-lactamase using ultra-performance liquid chromatography coupled with time-of-flight mass spectrometry. Journal of dairy science. 2014 Jul:97(7):4052-61. doi: 10.3168/jds.2014-7952. Epub 2014 May 2
[PubMed PMID: 24792795]
[20]
Soto E, Shoji S, Muto C, Tomono Y, Marshall S. Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment. British journal of clinical pharmacology. 2014 Mar:77(3):509-21. doi: 10.1111/bcp.12232. Epub
[PubMed PMID: 24102758]
[21]
Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2022 Jul 6:74(12):2089-2114. doi: 10.1093/cid/ciab1013. Epub
[PubMed PMID: 34864936]
[22]
Campoli-Richards DM, Brogden RN. Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use. Drugs. 1987 Jun:33(6):577-609
[PubMed PMID: 3038500]
[23]
Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 199: Use of Prophylactic Antibiotics in Labor and Delivery. Obstetrics and gynecology. 2018 Sep:132(3):e103-e119. doi: 10.1097/AOG.0000000000002833. Epub
[PubMed PMID: 30134425]
[25]
Nahata MC, Vashi VI, Swanson RN, Messig MA, Chung M. Pharmacokinetics of ampicillin and sulbactam in pediatric patients. Antimicrobial agents and chemotherapy. 1999 May:43(5):1225-9
[PubMed PMID: 10223940]
[26]
Gurvits GE, Tan A. Black hairy tongue syndrome. World journal of gastroenterology. 2014 Aug 21:20(31):10845-50. doi: 10.3748/wjg.v20.i31.10845. Epub
[PubMed PMID: 25152586]
[27]
Soar J, Pumphrey R, Cant A, Clarke S, Corbett A, Dawson P, Ewan P, Foëx B, Gabbott D, Griffiths M, Hall J, Harper N, Jewkes F, Maconochie I, Mitchell S, Nasser S, Nolan J, Rylance G, Sheikh A, Unsworth DJ, Warrell D, Working Group of the Resuscitation Council (UK). Emergency treatment of anaphylactic reactions--guidelines for healthcare providers. Resuscitation. 2008 May:77(2):157-69. doi: 10.1016/j.resuscitation.2008.02.001. Epub 2008 Mar 20
[PubMed PMID: 18358585]
[29]
. Ampicillin-Sulbactam. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:():
[PubMed PMID: 31643208]
[30]
Hornik CP, Benjamin DK Jr, Smith PB, Pencina MJ, Tremoulet AH, Capparelli EV, Ericson JE, Clark RH, Cohen-Wolkowiez M, Best Pharmaceuticals for Children Act—Pediatric Trials Network. Electronic Health Records and Pharmacokinetic Modeling to Assess the Relationship between Ampicillin Exposure and Seizure Risk in Neonates. The Journal of pediatrics. 2016 Nov:178():125-129.e1. doi: 10.1016/j.jpeds.2016.07.011. Epub 2016 Aug 10
[PubMed PMID: 27522443]
[31]
Oldfield EC 3rd. Clostridium difficile-associated diarrhea: risk factors, diagnostic methods, and treatment. Reviews in gastroenterological disorders. 2004 Fall:4(4):186-95
[PubMed PMID: 15580153]
[32]
Pak S, Kim SY, Kim SH, Joung JY, Park WS, Chung J, Lee KH, Seo HK. Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer. Frontiers in oncology. 2021:11():570077. doi: 10.3389/fonc.2021.570077. Epub 2021 Apr 2
[PubMed PMID: 33868985]
[33]
Cheng FJ, Syu FK, Lee KH, Chen FC, Wu CH, Chen CC. Correlation between drug-drug interaction-induced Stevens-Johnson syndrome and related deaths in Taiwan. Journal of food and drug analysis. 2016 Apr:24(2):427-432. doi: 10.1016/j.jfda.2015.11.009. Epub 2016 Jan 14
[PubMed PMID: 28911598]
[34]
Singh N, Yeh PJ. Suppressive drug combinations and their potential to combat antibiotic resistance. The Journal of antibiotics. 2017 Nov:70(11):1033-1042. doi: 10.1038/ja.2017.102. Epub 2017 Sep 6
[PubMed PMID: 28874848]
[35]
Dicks LMT, Mikkelsen LS, Brandsborg E, Marcotte H. Clostridium difficile, the Difficult "Kloster" Fuelled by Antibiotics. Current microbiology. 2019 Jun:76(6):774-782. doi: 10.1007/s00284-018-1543-8. Epub 2018 Aug 6
[PubMed PMID: 30084095]
[36]
Ciccarese G, Trave I, Herzum A, Parodi A, Drago F. Dermatological manifestations of Epstein-Barr virus systemic infection: a case report and literature review. International journal of dermatology. 2020 Oct:59(10):1202-1209. doi: 10.1111/ijd.14887. Epub 2020 Apr 28
[PubMed PMID: 32346863]
Level 3 (low-level) evidence
[37]
Kuruvilla M, Khan DA. Anaphylaxis to drugs. Immunology and allergy clinics of North America. 2015 May:35(2):303-19. doi: 10.1016/j.iac.2015.01.008. Epub 2015 Mar 3
[PubMed PMID: 25841553]
[38]
Ooi H, Asai Y, Sato Y. Risk evaluation of ampicillin/sulbactam-induced liver injury based on albumin-bilirubin score. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2023 Sep:29(9):900-904. doi: 10.1016/j.jiac.2023.06.003. Epub 2023 Jun 8
[PubMed PMID: 37301371]
[39]
King JD, Kern MH, Jaar BG. Extracorporeal Removal of Poisons and Toxins. Clinical journal of the American Society of Nephrology : CJASN. 2019 Sep 6:14(9):1408-1415. doi: 10.2215/CJN.02560319. Epub 2019 Aug 22
[PubMed PMID: 31439539]
[40]
Hodgman T, Dasta JF, Armstrong DK, Visconti JA, Reilley TE. Ampicillin-associated seizures. Southern medical journal. 1984 Oct:77(10):1323-5
[PubMed PMID: 6484655]
[41]
Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, Srinivasan A, Dellit TH, Falck-Ytter YT, Fishman NO, Hamilton CW, Jenkins TC, Lipsett PA, Malani PN, May LS, Moran GJ, Neuhauser MM, Newland JG, Ohl CA, Samore MH, Seo SK, Trivedi KK. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016 May 15:62(10):e51-77. doi: 10.1093/cid/ciw118. Epub 2016 Apr 13
[PubMed PMID: 27080992]
[42]
Burnham JP, Olsen MA, Stwalley D, Kwon JH, Babcock HM, Kollef MH. Infectious Diseases Consultation Reduces 30-Day and 1-Year All-Cause Mortality for Multidrug-Resistant Organism Infections. Open forum infectious diseases. 2018 Mar:5(3):ofy026. doi: 10.1093/ofid/ofy026. Epub 2018 Mar 15
[PubMed PMID: 29577058]
[43]
Polat EC, Koc A, Demirkan K. The role of the clinical pharmacist in the prevention of drug-induced acute kidney injury in the intensive care unit. Journal of clinical pharmacy and therapeutics. 2022 Dec:47(12):2287-2294. doi: 10.1111/jcpt.13811. Epub 2022 Nov 16
[PubMed PMID: 36394173]